From partner to part of the family: Takeda pulls the trigger on Maverick buyout

Takeda tapped Maverick Therapeutics and its T-cell engager platform in early 2017 to create new treatments for previously undruggable cancer targets. The $125 million deal also had a 5-year buyout option, which Takeda is now exercising for an undisclosed upfront fee and up to $525 million in development and regulatory milestones.